This medicine also employs LD or ULD of IFN-α and IL-2 in association with other actives, such as TNF-α at 5 CH, and it could be seen as an interesting immunotherapy adjuvant drug in the context of cancer treatments. The gene discussed is IL2; the disease is cancer.